Bovy, N., Halkein, J., Martial, J., Tabruyn, S., & Struman, I. (19 May 2012). Circulating microRNAs as a new way of communication between endothelial and tumor cells [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (19 May 2012). MicroRNA-146a, a downstream effector of 16K prolactin, is a therapeutic target and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (April 2012). MicroRNA-146a is a causative factor and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. Biomedica, Liège, Belgium. |
Bovy, N., Halkein, J., Martial, J., Tabruyn, S., & Struman, I. (April 2012). Circulating microRNAs as a new way of communication between endothelial and tumor cells [Poster presentation]. Biomedica, Liège, Belgium. |
Halkein, J., Tabruyn, S., Haghikia, A., Castermans, K., Malvaux, L., Lambert, V., Labidi, S., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (January 2012). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Keystone symposia on Angiogenesis advances in basic sciences and therapeutic applications, Snowbird Resort, Snowbird, Utah, United States. |
![]() ![]() | Struman, I., Halkein, J., Tabruyn, S., Haghiskia, A., Hoch, M., Nguyen, N.-Q.-N., Malvaux, L., sliwa, K., Noël, A., Martial, J., & Hilfiker-kleiner, D. (2012). MicroRNA-146a, a downstream effector of 16kDa prolactin, impairs the endothelium-cardiomyocyte cross-talk in peripartum cardiomyopathy. In FASEB meeting:the Growth Hormone/Prolactin Family in Biology and Disease. ![]() |
![]() ![]() | Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (07 November 2011). The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. PLoS ONE, 6 (11), 27318-27318. doi:10.1371/journal.pone.0027318 ![]() |
Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (May 2011). The antiangiogenic 16K prolactin disturbs functional tumor neovascularization by affecting vessel maturation [Poster presentation]. 4th International Meeting on Angiogenesis, Amsterdam, Netherlands. |
Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (March 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. IVth International Meeting on Angiogenesis, Amsterdam, Netherlands. |
Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (March 2011). Mir-146a : A new angiostatic miRNA with tumor-suppressive properties [Poster presentation]. IVth International Meeting on Angiogenesis, Amsterdam, Netherlands. |
Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (February 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Keystone Symposia : MicroRNAs and Human Disease, Banff, Alberta, Canada. |
Halkein, J., Bovy, N., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (February 2011). MiR-146a: an angiostatic miRNA with tumor-suppressive properties [Poster presentation]. Keystone Symposia : MicroRNAs and Non-Coding RNAs and Cancer, Banff, Alberta, Canada. |
![]() ![]() | COLLIGNON, J., Struman, I., Tabruyn, S., Josse, C., Boukerroucha, M., JERUSALEM, G., & BOURS, V. (2011). Aspects moléculaires du cancer du sein triple négatif et les implications thérapeutiques. Revue Médicale de Liège, 66 (5-6), 393-396. ![]() |
Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (January 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Giga-Day Symposia, Liège, Belgium. |
![]() ![]() | Fuxe, J., Tabruyn, S., Colton, K., Zaid, H., Adams, A., Baluk, P., Lashnits, E., Morisada, T., Le, T., O'Brien, S., Epstein, D. M., Koh, G. Y., & McDonald, D. M. (2011). Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. American Journal of Pathology, 178 (6), 2897-909. doi:10.1016/j.ajpath.2011.02.008 ![]() |
Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (October 2010). Mir-146a : A new angiostatic miRNA with tumor-suppressive properties [Poster presentation]. Frontiers in Tumor Progression, Madrid, Spain. |
Halkein, J., Tabruyn, S., Malvaux, L., Sabatel, C., Martial, J., & Struman, I. (21 May 2010). miR-146a: an anti-angiogenic miRNA regulated by NF-kB [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
![]() ![]() | Sabatel, C., Cornet, A., Tabruyn, S., Malvaux, L., Castermans, K., Martial, J., & Struman, I. (2010). Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Molecular Cancer, 9 (1), 231. doi:10.1186/1476-4598-9-231 ![]() |
![]() ![]() | Fuxe, J., Lashnits, E., O'Brien, S., Baluk, P., Tabruyn, S., Kuhnert, F., Kuo, C., Thurston, G., & McDonald, D. M. (2010). Angiopoietin/Tie2 signaling transforms capillaries into venules primed for leukocyte trafficking in airway inflammation. American Journal of Pathology, 176 (4), 2009-18. doi:10.2353/ajpath.2010.090976 ![]() |
![]() ![]() | Tabruyn, S., Colton, K., Morisada, T., Fuxe, J., Wiegand, S. J., Thurston, G., Coyle, A. J., Connor, J., & McDonald, D. M. (2010). Angiopoietin-2-Driven Vascular Remodeling in Airway Inflammation. American Journal of Pathology. doi:10.2353/ajpath.2010.100059 ![]() |
![]() ![]() | Tabruyn, S., Memet, S., Ave, P., Verhaeghe, C., Mayo, K. H., Struman, I., Martial, J., & Griffioen, A. W. (2009). NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Molecular Cancer Therapeutics, 8 (9), 2645-54. doi:10.1158/1535-7163.MCT-09-0383 ![]() |
![]() ![]() | Sennino, B., Kuhnert, F., Tabruyn, S., Mancuso, M. R., Hu-Lowe, D. D., Kuo, C. J., & McDonald, D. M. (2009). Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Research, 69 (10), 4527-36. doi:10.1158/0008-5472.CAN-08-3779 ![]() |
Sabatel, C., Tabruyn, S., Cornet, A., Martial, J., & Struman, I. (30 March 2008). Study of the role of Sprouty1 in the regulation of angiogenesis [Poster presentation]. GIGA-Cancer Day, Liège, Belgium. |
![]() ![]() | Tabruyn, S., & Griffioen, A. W. (2008). NF-kappa B: a new player in angiostatic therapy. Angiogenesis, 11 (1), 101-6. doi:10.1007/s10456-008-9094-4 ![]() |
![]() ![]() | Castermans, K., Tabruyn, S., Zeng, R., van Beijnum, J. R., Eppolito, C., Leonard, W. J., Shrikant, P. A., & Griffioen, A. W. (2008). Angiostatic activity of the antitumor cytokine interleukin-21. Blood, 112 (13), 4940-7. doi:10.1182/blood-2007-09-113878 ![]() |
![]() ![]() | Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (December 2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Molecular Therapy, 15 (12), 2094-2100. doi:10.1038/sj.mt.6300294 ![]() |
![]() ![]() | Verhaeghe, C., Tabruyn, S., Oury, C., Bours, V., & Griffioen, A. W. (2007). Intrinsic pro-angiogenic status of cystic fibrosis airway epithelial cells. Biochemical and Biophysical Research Communications, 356 (3), 745-749. doi:10.1016/j.bbrc.2007.02.166 ![]() |
Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Gordon research on angiogenesis, Newport, United States - Rhode Island. |
![]() ![]() | Tabruyn, S., & Griffioen, A. W. (2007). Molecular pathways of angiogenesis inhibition. Biochemical and Biophysical Research Communications, 355 (1), 1-5. doi:10.1016/j.bbrc.2007.01.123 ![]() |
![]() ![]() | Tabruyn, S., & Griffioen, A. W. (2007). A new role for NF-kappaB in angiogenesis inhibition. Cell Death and Differentiation, 14 (8), 1393-7. doi:10.1038/sj.cdd.4402156 ![]() |
Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., FOIDART, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Keystone symposia: Host cell response to cancer, Bozeman, United States - Montana. |
Sabatel, C., Tabruyn, S., Cornet, A., Griffioen, A., Martial, J., & Struman, I. (January 2007). Study of the molecular mechanisms involved in the response of tumor and host to the treatment with the antiangiogenic factor 16K prolactin [Poster presentation]. Host cell response to cancer, Keystone, United States. |
Tabruyn, S., Sabatel, C., Nguyen, N.-Q.-N., Verhaeghe, Castermans, K., Malvaux, L., Griffioen, A. W., Martial, J., & Struman, I. (2007). The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Molecular Endocrinology, 21 (6), 1422-9. doi:10.1210/me.2007-0021 ![]() |
![]() ![]() | Olivier, S., Close, P., Castermans, E., de Leval, L., Tabruyn, S., Chariot, A., Malaise, M., Merville, M.-P., Bours, V., & Franchimont, N. (May 2006). Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Molecular Pharmacology, 69 (5), 1615-1623. doi:10.1124/mol.105.020479 ![]() |
Cornet, A., Nguyen, N.-Q.-N., Lion, M., Tabruyn, S., Sabatel, C., Kinet, V., Noël, A., Beckers, M.-C., Struman, I., & Martial, J. (May 2006). Molecular profiling of 16K PRL treated tumours by an antibody-array approach [Poster presentation]. Bioforum, Liège, Belgium. |
Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Evaluation of 16K Prolactin to prevent metastatic spread through inhibition of angiogenesis [Poster presentation]. Gordon Research Conference: Prolactin Family, Ventura, United States - California. |
Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Adenovirus-mediated gene transfer of 16K prolactin inhibits B16-F10 tumor growth and metastasis [Poster presentation]. Bioforum, Liège, Belgium. |
![]() ![]() | Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Lair, F., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103 (39), 14319-14324. doi:10.1073/pnas.0606638103 ![]() |
Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Tilted peptides of PRL/GH family and their potential role in angiogenesis [Poster presentation]. Bioforum, Liège, Belgium. |
Tabruyn, S., Nguyen, N.-Q.-N., Cornet, A., Martial, J., & Struman, I. (July 2005). The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G(0)-G(1) and the G(2)-M phases. Molecular Endocrinology, 19 (7), 1932-1942. doi:10.1210/me.2004-0515 ![]() |
![]() ![]() | Piwnica, D., Touraine, P., Struman, I., Tabruyn, S., Bolbach, G., Clapp, C., Martial, J., Kelly, P. A., & Goffin, V. (October 2004). Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: Study of their antiangiogenic properties and physiological relevance. Molecular Endocrinology, 18 (10), 2522-2542. doi:10.1210/me.2004-0200 ![]() |
Tabruyn, S., Sorlet, C. M., Rentier-Delrue, F., Bours, V., Weiner, R. I., Martial, J., & Struman, I. (September 2003). The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappa B. Molecular Endocrinology, 17 (9), 1815-1823. doi:10.1210/me.2003-0132 ![]() |
Tabruyn, S., Sorlet, C., Georges, A., Rentier-Delrue, F., Martial, J., & Struman, I. (2003). 16K hPRL prevents angiogenesis by inducing both apoptosis and cell cycle arrest of endothelial cells [Poster presentation]. Euroconférences: Angiogenesis 2, Paris, France. |